German Insurers Want End To Free Pricing In Amnog Review
Drug Prices Are Claimed To Be ‘Out Of Control’
Executive Summary
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
You may also be interested in...
German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments
Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.
European Health Data Space Talks Falter Over Opt-Out Issue
The pharmaceutical industry has warned co-legislators against any hasty compromises that could impact the competitiveness of EU research.
Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.